Raghav Sundar, MBBS, MRCP, MMed, National University Health System, Singapore, discusses the development of a new device that may be able to reduce chemotherapy-induced peripheral neuropathy (CIPN).
Raghav Sundar, MBBS, MRCP, MMed, National University Health System, Singapore, discusses the development of a new device that may be able to reduce chemotherapy-induced peripheral neuropathy (CIPN).
The device that was developed covers and cools patients’ arms and legs during chemotherapy infusion. By decreasing the temperature and thereby the blood flow, a smaller amount of chemotherapy will end up in the extremities, preventing CIPN.
A clinical trial was conducted that involved patients with breast cancer who were receiving weekly placlitaxel (Abraxane) infusions. Patients were monitored with temperature sensors and nerve-conducting studies. The proof-of-concept study showed that this may be a promising method to reduce CIPN.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”